Related Experiment Video
Updated: Jul 16, 2025
05:08
Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
Published on: October 3, 2019
11.2K
Immunomodulation and immunopharmacology in heart failure
George Markousis-Mavrogenis1, Lukas Baumhove1, Ali A Al-Mubarak1
1Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
Nature Reviews. Cardiology
|September 14, 2023
Summary
The immune system plays a key role in heart failure, but is underutilized therapeutically. Understanding how current heart failure treatments impact immunity is crucial for developing new immunomodulatory therapies.
Area of Science:
- Cardiology
- Immunology
- Pharmacology
Background:
- The immune system is integral to heart failure development and progression.
- Current heart failure treatments have significant, often overlooked, immunomodulatory effects.
- The therapeutic potential of targeting the immune system in heart failure remains largely untapped.
Purpose of the Study:
- To review the immunomodulatory effects of established heart failure treatments.
- To provide a framework for developing novel immunomodulatory therapies for heart failure.
- To identify patient subpopulations and future therapeutic targets for immunomodulation in heart failure.
Main Methods:
- Comprehensive literature review of existing evidence-based heart failure treatments and their impact on the immune system.
- Analysis of completed and ongoing clinical trials investigating immunomodulatory therapies for heart failure.
- Identification of potential future therapeutic targets and research directions.
Main Results:
- Evidence-based heart failure therapies possess diverse immunomodulatory actions beyond their primary mechanisms.
- Specific patient groups may derive greater benefit from immunomodulatory interventions.
- Several promising immunomodulatory targets and ongoing clinical trials are identified.
Conclusions:
- A deeper understanding of treatment-induced immunomodulation is essential for optimizing heart failure care.
- Leveraging existing therapies' immune effects and exploring novel immunomodulators can advance heart failure treatment.
- Future research should focus on personalized immunomodulatory strategies for heart failure patients.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
460
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
460
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:30Heart Failure V: Medical Management
12
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
12
01:26Heart Failure Drugs: Inotropic Agents
617
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
617
01:29Heart Failure II: Pathophysiology
15
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15
01:22Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16